Nicholas Investment Partners LP Invests $18.21 Million in Dianthus Therapeutics, Inc. $DNTH

Nicholas Investment Partners LP acquired a new stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 186,769 shares of the company’s stock, valued at approximately $18,206,000. Dianthus Therapeutics makes up approximately 1.0% of Nicholas Investment Partners LP’s portfolio, making the stock its 25th biggest position. Nicholas Investment Partners LP owned 0.34% of Dianthus Therapeutics as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in DNTH. BlackRock Inc. bought a new position in Dianthus Therapeutics during the 2nd quarter worth about $401,990,000. Wellington Management Group LLP raised its holdings in shares of Dianthus Therapeutics by 3,366.9% in the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after purchasing an additional 2,503,311 shares in the last quarter. Vestal Point Capital LP raised its holdings in shares of Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after purchasing an additional 1,499,931 shares in the last quarter. State Street Corp lifted its position in shares of Dianthus Therapeutics by 124.7% in the 4th quarter. State Street Corp now owns 1,507,619 shares of the company’s stock worth $62,129,000 after purchasing an additional 836,571 shares during the period. Finally, Polar Capital Holdings Plc purchased a new stake in shares of Dianthus Therapeutics in the 3rd quarter worth approximately $29,434,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Marino Garcia sold 166,000 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $108.11, for a total value of $17,946,260.00. Following the completion of the transaction, the chief executive officer directly owned 65,292 shares of the company’s stock, valued at $7,058,718.12. This trade represents a 71.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Ryan Savitz sold 31,249 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the completion of the sale, the executive vice president owned 31,249 shares of the company’s stock, valued at $3,157,086.47. This trade represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 287,084 shares of company stock valued at $29,615,923. 3.02% of the stock is owned by company insiders.

Dianthus Therapeutics Price Performance

Shares of NASDAQ:DNTH opened at $110.07 on Tuesday. The business’s 50-day moving average is $101.30 and its 200 day moving average is $85.62. Dianthus Therapeutics, Inc. has a 1 year low of $22.81 and a 1 year high of $117.88. The firm has a market capitalization of $6.02 billion, a P/E ratio of -26.52 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The business had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.30 million. On average, analysts expect that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on DNTH shares. Wedbush lifted their price objective on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. Wall Street Zen raised shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $131.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $124.27.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.